儿童烧伤与手术患者的药物基因组学基因-药物关联
该研究分析了30例儿童烧伤与手术患者的遗传(19例全外显子组和11例全基因组)与用药数据,以识别药物基因-药物关联。19例患者在一个或多个以下基因中检出预测功能改变的变异:CYP2C9、CYP2C19、CYP2D6和CYP3A4。研究提示遗传变异可能部分解释药物疗效的巨大变异性,并提示未来药物基因组学研究可能优化给药方案。
要点
- 30例儿童烧伤与手术患者中,19例检出CYP2C9、CYP2C19、CYP2D6或CYP3A4预测功能改变变异。
- 多数变异为功能降低,但部分患者携带CYP2C19快代谢或超快代谢变异。
- 约三分之一受检者在各主要药物代谢通路中具有功能影响性基因型。
核心结论
- 本研究提示遗传变异可能部分解释药物疗效的巨大变异性,并提示未来药物基因组学研究可能优化给药方案。
研究设计与样本
- 研究分析了30例儿童烧伤与手术患者的遗传数据(19例全外显子组和11例全基因组)与用药数据,以识别药物基因-药物关联。
主要发现
- 19例患者在一个或多个以下基因中检出预测功能改变:CYP2C9、CYP2C19、CYP2D6和CYP3A4。
- 多数患者为功能降低,但部分患者携带CYP2C19快代谢或超快代谢变异。
- 住院期间使用的部分依赖这些通路的药物包括氢可酮、羟考酮、美沙酮、布洛芬、酮咯酸、塞来昔布、地西泮、法莫替丁、苯海拉明和格隆溴铵。
- 约三分之一受检者在各主要药物代谢通路中具有功能影响性基因型。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Management of critically ill patients requires simultaneous administration of many medications. Treatment for patient comorbidities may lead to drug-drug interactions which decrease drug efficacy or increase adverse reactions. Current practices rely on a one-size-fits-all dosing approach. Pharmacogenetic testing is generally reserved for addressing problems rather than used proactively to optimize care. We hypothesized that burn and surgery patients will have one or more genetic variants in drug metabolizing pathways used by one or more medications administered during the patient's hospitalization. The aim of this study was to determine the frequency of variants with abnormal function in the primary drug pathways and identify which medications may be impacted. Genetic (19 whole exome and 11 whole genome) and medication data from 30 pediatric burn and surgery patients were analyzed to identify pharmacogene-drug associations. Nineteen patients were identified with predicted altered function in one or more of the following genes: CYP2C9, CYP2C19, CYP2D6, and CYP3A4. The majority had decreased function, except for several patients with CYP2C19 rapid or ultrarapid variants. Some drugs administered during hospitalization that rely on these pathways include hydrocodone, oxycodone, methadone, ibuprofen, ketorolac, celecoxib, diazepam, famotidine, diphenhydramine, and glycopyrrolate. Approximately one-third of the patients tested had functionally impactful genotypes in each of the primary drug metabolizing pathways. This study suggests that genetic variants may in part explain the vast variability in drug efficacy and suggests that future pharmacogenetics research may optimize dosing regimens.
引用
- Grimsrud KN, Davis RR, Tepper CG, et al. Pharmacogenetic Gene-Drug Associations in Pediatric Burn and Surgery Patients. J Burn Care Res. 2022. PMID: 35639664. doi:10.1093/jbcr/irac062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。